Ergoteles LLC: TFX position timeline
Available 13F reports, 13D and 13G stakes and each Form 3, 4 and 5 line of Ergoteles LLC on TFX, newest first. How the timeline and the estimate are built.
Ergoteles LLC held 0 TFX shares at 2023-09-30 per its 13F-HR filed 2023-11-14.
the latest 13F is the newest step
- period ended2023-09-3013F 0 sharesChange vs previous 13F -2,782 shares
13F-HR 0001569136-23-000005 filed by Ergoteles LLC
Filed (acceptance time not in the bulk data set), ingestedAcceptance time not in the bulk data set (spec §4.2).
Exited: the 13F for this period no longer lists the position.
- period ended2023-06-3013F 2,782 sharesChange vs previous 13F +2,782 shares
0.03% of the 13F portfolio, value $673,327.
13F-HR 0001569136-23-000004 filed by Ergoteles LLC
Filed (acceptance time not in the bulk data set), ingestedAcceptance time not in the bulk data set (spec §4.2).
- period ended2023-03-3113F 0 sharesChange vs previous 13F -2,958 shares
13F-HR 0001569136-23-000002 filed by Ergoteles LLC
Filed (acceptance time not in the bulk data set), ingestedAcceptance time not in the bulk data set (spec §4.2).
Exited: the 13F for this period no longer lists the position.
- period ended2022-12-3113F 2,958 sharesChange vs previous 13F +2,958 shares
0.03% of the 13F portfolio, value $738,406.
13F-HR 0001569136-23-000001 filed by Ergoteles LLC
Filed (acceptance time not in the bulk data set), ingestedAcceptance time not in the bulk data set (spec §4.2).
- period ended2022-09-3013F 0 sharesChange vs previous 13F -1,696 shares
13F-HR 0001569136-22-000007 filed by Ergoteles LLC
Filed (acceptance time not in the bulk data set), ingestedAcceptance time not in the bulk data set (spec §4.2).
Exited: the 13F for this period no longer lists the position.
- period ended2022-06-3013F 1,696 sharesChange vs previous 13F not available
0.01% of the 13F portfolio, value $417,000.
13F-HR 0001569136-22-000006 filed by Ergoteles LLC
Filed (acceptance time not in the bulk data set), ingestedAcceptance time not in the bulk data set (spec §4.2).